Athira Pharma, Inc. (ATHA)
2025-06-30 | ||||
|---|---|---|---|---|
| Unrealized (loss) gain on available-for-sale securities | 1 | |||
| Other income, net | 325 | |||
| Research and development | 3,661 | |||
| General and administrative | 3,630 | |||
| Total operating expenses | 7,291 | |||
| Loss from operations | -7,291 | |||
| Net loss | -6,966 | |||
| Comprehensive loss attributable to common stockholders | -6,965 | |||
| Earnings per share, basic | -0.18 | |||
| Earnings per share, diluted | -0.18 | |||
| Weighted average number of shares outstanding, basic | 39,092,961 | |||
| Weighted average number of shares outstanding, diluted | 39,092,961 | |||